Cartesian Therapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Cartesian Therapeutics amended and restated its 2018 Employment Inducement Incentive Award Plan, effective as a standalone equity compensation vehicle for new or rehired employees. The plan permits grants of non-qualified stock options, restricted stock units, restricted stock, and cash-based awards up to an overall share limit of 1,726,666 shares. The plan operates under NASDAQ Rule 5635(c)(4) exemption, requiring no stockholder approval. Specific grant details (recipient names, dollar amounts, dates, vesting schedules) are not disclosed in this template document—individual award agreements would contain those terms.
Why this rating
Plan amendment is administrative boilerplate for equity administration. No specific grants, dollar figures, or recipient names disclosed. At ~$109M market cap, even if fully utilized, 1.7M shares at typical startup valuations represents routine HR mechanics, not material business change.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.